Chief Executive, Mesoblast
| Role | Organisation | Sources |
|---|---|---|
| Chief Executive | Mesoblast | Biotech Dispatch, @AuManufacturing |
Stories naming Dr Silviu Itescu. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Mesoblast has finished dosing all 350 patients in its phase 3 trial of rexlemestrocel-L for degenerative disc disease, with data due mid-2027 and a possible US biologics application to follow.
Mesoblast says the US FDA has confirmed its clinical data now supports refiling the remestemcel-L biologics application for pediatric patients, with resubmission planned next quarter; shares rose on the announcement.